UBS Maintains Neutral on Alignment Healthcare, Lowers Price Target to $9

UBS analyst Jonathan Yong has maintained a Neutral rating on Alignment Healthcare (NASDAQ: ALHC) and reduced the price target from $22 to $9. This adjustment reflects a significant decrease in expected valuation for the company.